AbbVie Inc. Files Q2 2024 10-Q Report
Ticker: ABBV · Form: 10-Q · Filed: 2024-08-07T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, financials, pharmaceuticals
Related Tickers: ABBV
TL;DR
**AbbVie Q2 10-Q filed. Financials are in.**
AI Summary
AbbVie Inc. filed its 10-Q for the period ending June 30, 2024, reporting on its financial performance. The company's fiscal year ends on December 31, 2024. Key financial details and operational updates are provided in this quarterly report.
Why It Matters
This filing provides investors and analysts with the latest financial data and operational insights for AbbVie Inc., crucial for understanding the company's current health and future prospects.
Risk Assessment
Risk Level: low — This is a standard quarterly financial filing (10-Q) and does not inherently present new risks beyond those typically associated with public companies.
Key Players & Entities
- AbbVie Inc. (company) — Filer of the 10-Q report
- 20240630 (date) — End of the reporting period
- 20240807 (date) — Date of filing
- 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL 60064 (address) — AbbVie's business and mailing address
FAQ
What is the reporting period for this 10-Q filing?
The Conformed Period of Report is 20240630, indicating the filing covers the period ending June 30, 2024.
When was this 10-Q filed with the SEC?
This 10-Q was filed on 20240807.
What is AbbVie Inc.'s fiscal year end?
AbbVie Inc.'s fiscal year ends on December 31.
What is AbbVie Inc.'s Standard Industrial Classification (SIC) code?
AbbVie Inc.'s SIC code is 2834, which corresponds to Pharmaceutical Preparations.
Where is AbbVie Inc. headquartered?
AbbVie Inc.'s business address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, STATE: IL, ZIP: 60064.
From the Filing
0001551152-24-000031.txt : 20240807 0001551152-24-000031.hdr.sgml : 20240807 20240807150051 ACCESSION NUMBER: 0001551152-24-000031 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 79 CONFORMED PERIOD OF REPORT: 20240630 FILED AS OF DATE: 20240807 DATE AS OF CHANGE: 20240807 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AbbVie Inc. CENTRAL INDEX KEY: 0001551152 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 320375147 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-35565 FILM NUMBER: 241183091 BUSINESS ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 BUSINESS PHONE: (847) 932-7900 MAIL ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 10-Q 1 abbv-20240630.htm 10-Q abbv-20240630 0001551152 false December 31 2024 Q2 http://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#InterestIncomeExpenseNonoperatingNet http://fasb.org/us-gaap/2024#InterestIncomeExpenseNonoperatingNet http://fasb.org/us-gaap/2024#ForeignCurrencyTransactionGainLossBeforeTax http://fasb.org/us-gaap/2024#ForeignCurrencyTransactionGainLossBeforeTax http://fasb.org/us-gaap/2024#InterestIncomeExpenseNonoperatingNet http://fasb.org/us-gaap/2024#InterestIncomeExpenseNonoperatingNet http://fasb.org/us-gaap/2024#ForeignCurrencyTransactionGainLossBeforeTax http://fasb.org/us-gaap/2024#ForeignCurrencyTransactionGainLossBeforeTax http://fasb.org/us-gaap/2024#ForeignCurrencyTransactionGainLossBeforeTax http://fasb.org/us-gaap/2024#ForeignCurrencyTransactionGainLossBeforeTax http://fasb.org/us-gaap/2024#InterestIncomeExpenseNonoperatingNet http://fasb.org/us-gaap/2024#InterestIncomeExpenseNonoperatingNet http://fasb.org/us-gaap/2024#MoneyMarketFundsMember http://fasb.org/us-gaap/2024#MoneyMarketFundsMember http://fasb.org/us-gaap/2024#Revenues http://fasb.org/us-gaap/2024#Revenues http://fasb.org/us-gaap/2024#Revenues http://fasb.org/us-gaap/2024#Revenues http://fasb.org/us-gaap/2024#Revenues http://fasb.org/us-gaap/2024#Revenues http://fasb.org/us-gaap/2024#Revenues http://fasb.org/us-gaap/2024#Revenues 1 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure iso4217:EUR iso4217:SEK iso4217:CAD iso4217:CHF abbv:wholesaler abbv:lawsuit abbv:company abbv:claim abbv:claims abbv:segment 0001551152 2024-01-01 2024-06-30 0001551152 us-gaap:CommonStockMember exch:XNYS 2024-01-01 2024-06-30 0001551152 us-gaap:CommonStockMember exch:XCHI 2024-01-01 2024-06-30 0001551152 abbv:Sec0.750SeniorNotesDue2027Member exch:XNYS 2024-01-01 2024-06-30 0001551152 exch:XNYS abbv:Sec2.125SeniorNotesdue2028Member 2024-01-01 2024-06-30 0001551152 abbv:Sec2625SeniorNotesDue2028Member exch:XNYS 2024-01-01 2024-06-30 0001551152 abbv:Sec2125SeniorNotesDue2029Member exch:XNYS 2024-01-01 2024-06-30 0001551152 exch:XNYS abbv:Sec1.250SeniorNotesdue2031Member 2024-01-01 2024-06-30 0001551152 2024-07-29 0001551152 2024-04-01 2024-06-30 0001551152 2023-04-01 2023-06-30 0001551152 2023-01-01 2023-06-30 0001551152 2024-06-30 0001551152 2023-12-31 0001551152 us-gaap:CommonStockMember 2023-03-31 0001551152 us-gaap:TreasuryStockCommonMember 2023-03-31 0001551152 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001551152 us-gaap:RetainedEarningsMember 2023-03-31 0001551152 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001551152 us-gaap:NoncontrollingInterestMember 2023-03-31 0001551152 2023-03-31 0001551152 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001551152 us-gaap:TreasuryStockCommonMember 2023-04-01 2023-06-30 0001551152 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001551152 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001551152 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0001551152 us-gaap:NoncontrollingInterestMember 2023-04-01 2023-06-30